Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global $36.46 Billion HIV Drugs Markets, 2015-2020, 2020-2025F, 2030F | ||
By: PR Newswire Association LLC. - 12 May 2021 | Back to overview list |
|
DUBLIN, May 12, 2021 /PRNewswire/ -- The "HIV Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the HIV drugs market are ViiV Healthcare, Gilead Sciences, Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen (Johnson & Johnson), F. HOFFMANN-LA ROCHE LTD, Boehringer Ingelheim (C.H. Boehringer Sohn AG & Ko. KG), AbbVie, Inc., GlaxoSmithKline plc, and Mylan Pharmaceuticals. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $36.46 billion in 2025 at a CAGR of 3.9%. These drugs come with both short-term side effects (diarrhea, difficulty in sleeping, dizziness, fatigue, headache, muscle pain) and long-term side effects (depression, diabetes, heart disease, insomnia). There are several side effects associated with the therapy, thus impacting the growth of the market. Based on drug class, drugs are segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Others. Multi-class Combination Products is the rising burden of HIV and new drug approval. According to WHO, around 690 000 people died from HIV in 2019. Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets. According to WHO, 26 million people were diagnosed with HIV/AIDS in 2020, whereas, 32.7 million people died of AIDS related illness at the end of 2019. The federal government agencies, and various associations across the globe have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care.
6.2. Global HIV Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
6.3. Global HIV Drugs Market, Segmentation By Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7. HIV Drugs Market Regional And Country Analysis
For more information about this report visit https://www.researchandmarkets.com/r/97y6fm Media Contact: Research and Markets View original content:http://www.prnewswire.com/news-releases/global-36-46-billion-hiv-drugs-markets-2015-2020--2020-2025f-2030f-301290074.html SOURCE Research and Markets |
||
|
||
Copyright 2021 PR Newswire Association LLC. | Back to overview list |